Anti-p53 antibodies in patients with dermatomyositis/polymyositis. 2007

Yoshihiro Mimura, and Norihito Yazawa, and Zenshirou Tamaki, and Ryuichi Ashida, and Masatoshi Jinnin, and Yoshihide Asano, and Yayoi Tada, and Masahide Kubo, and Hironobu Ihn, and Kunihiko Tamaki
Department of Dermatology, Faculty of Medicine, University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan.

Dermatomyositis/polymyositis (DM/PM), which is often accompanied by various immunological abnormalities, was reported to be associated with an increased incidence of malignancies. In this study, we analyzed serum levels of anti-p53 antibody (anti-p53 Ab) in DM/PM patients and in normal controls. Serum levels of anti-p53 Abs were significantly higher in DM/PM patients than those in healthy controls. However, there was no significant difference between serum levels in patients with malignancies and those in patients without malignancies. Anti-p53 Abs were positive in 13% (4 out of 31) of the DM/PM patients. Of these four patients, only one had an internal malignancy. Immunoglobulin G levels were significantly higher in patients positive for anti-p53 Ab than those who were not. These results seemed to suggest that the presence of anti-p53 Abs in DM/PM patients is due to immunological abnormalities in this disease.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D003882 Dermatomyositis A subacute or chronic inflammatory disease of muscle and skin, marked by proximal muscle weakness and a characteristic skin rash. The illness occurs with approximately equal frequency in children and adults. The skin lesions usually take the form of a purplish rash (or less often an exfoliative dermatitis) involving the nose, cheeks, forehead, upper trunk, and arms. The disease is associated with a complement mediated intramuscular microangiopathy, leading to loss of capillaries, muscle ischemia, muscle-fiber necrosis, and perifascicular atrophy. The childhood form of this disease tends to evolve into a systemic vasculitis. Dermatomyositis may occur in association with malignant neoplasms. (From Adams et al., Principles of Neurology, 6th ed, pp1405-6) Polymyositis-Dermatomyositis,Dermatomyositis, Adult Type,Dermatomyositis, Childhood Type,Dermatopolymyositis,Juvenile Dermatomyositis,Juvenile Myositis,Adult Type Dermatomyositis,Childhood Type Dermatomyositis,Dermatomyositis, Juvenile,Myositis, Juvenile,Polymyositis Dermatomyositis
D004797 Enzyme-Linked Immunosorbent Assay An immunoassay utilizing an antibody labeled with an enzyme marker such as horseradish peroxidase. While either the enzyme or the antibody is bound to an immunosorbent substrate, they both retain their biologic activity; the change in enzyme activity as a result of the enzyme-antibody-antigen reaction is proportional to the concentration of the antigen and can be measured spectrophotometrically or with the naked eye. Many variations of the method have been developed. ELISA,Assay, Enzyme-Linked Immunosorbent,Assays, Enzyme-Linked Immunosorbent,Enzyme Linked Immunosorbent Assay,Enzyme-Linked Immunosorbent Assays,Immunosorbent Assay, Enzyme-Linked,Immunosorbent Assays, Enzyme-Linked
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D001323 Autoantibodies Antibodies that react with self-antigens (AUTOANTIGENS) of the organism that produced them. Autoantibody
D016022 Case-Control Studies Comparisons that start with the identification of persons with the disease or outcome of interest and a control (comparison, referent) group without the disease or outcome of interest. The relationship of an attribute is examined by comparing both groups with regard to the frequency or levels of outcome over time. Case-Base Studies,Case-Comparison Studies,Case-Referent Studies,Matched Case-Control Studies,Nested Case-Control Studies,Case Control Studies,Case-Compeer Studies,Case-Referrent Studies,Case Base Studies,Case Comparison Studies,Case Control Study,Case Referent Studies,Case Referrent Studies,Case-Comparison Study,Case-Control Studies, Matched,Case-Control Studies, Nested,Case-Control Study,Case-Control Study, Matched,Case-Control Study, Nested,Case-Referent Study,Case-Referrent Study,Matched Case Control Studies,Matched Case-Control Study,Nested Case Control Studies,Nested Case-Control Study,Studies, Case Control,Studies, Case-Base,Studies, Case-Comparison,Studies, Case-Compeer,Studies, Case-Control,Studies, Case-Referent,Studies, Case-Referrent,Studies, Matched Case-Control,Studies, Nested Case-Control,Study, Case Control,Study, Case-Comparison,Study, Case-Control,Study, Case-Referent,Study, Case-Referrent,Study, Matched Case-Control,Study, Nested Case-Control
D016159 Tumor Suppressor Protein p53 Nuclear phosphoprotein encoded by the p53 gene (GENES, P53) whose normal function is to control CELL PROLIFERATION and APOPTOSIS. A mutant or absent p53 protein has been found in LEUKEMIA; OSTEOSARCOMA; LUNG CANCER; and COLORECTAL CANCER. p53 Tumor Suppressor Protein,Cellular Tumor Antigen p53,Oncoprotein p53,TP53 Protein,TRP53 Protein,p53 Antigen,pp53 Phosphoprotein,Phosphoprotein, pp53

Related Publications

Yoshihiro Mimura, and Norihito Yazawa, and Zenshirou Tamaki, and Ryuichi Ashida, and Masatoshi Jinnin, and Yoshihide Asano, and Yayoi Tada, and Masahide Kubo, and Hironobu Ihn, and Kunihiko Tamaki
May 1999, The Journal of investigative dermatology,
Yoshihiro Mimura, and Norihito Yazawa, and Zenshirou Tamaki, and Ryuichi Ashida, and Masatoshi Jinnin, and Yoshihide Asano, and Yayoi Tada, and Masahide Kubo, and Hironobu Ihn, and Kunihiko Tamaki
January 2014, Clinical and experimental rheumatology,
Yoshihiro Mimura, and Norihito Yazawa, and Zenshirou Tamaki, and Ryuichi Ashida, and Masatoshi Jinnin, and Yoshihide Asano, and Yayoi Tada, and Masahide Kubo, and Hironobu Ihn, and Kunihiko Tamaki
February 1992, Zhonghua Minguo wei sheng wu ji mian yi xue za zhi = Chinese journal of microbiology and immunology,
Yoshihiro Mimura, and Norihito Yazawa, and Zenshirou Tamaki, and Ryuichi Ashida, and Masatoshi Jinnin, and Yoshihide Asano, and Yayoi Tada, and Masahide Kubo, and Hironobu Ihn, and Kunihiko Tamaki
October 2019, Journal of dermatological science,
Yoshihiro Mimura, and Norihito Yazawa, and Zenshirou Tamaki, and Ryuichi Ashida, and Masatoshi Jinnin, and Yoshihide Asano, and Yayoi Tada, and Masahide Kubo, and Hironobu Ihn, and Kunihiko Tamaki
September 2019, Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases,
Yoshihiro Mimura, and Norihito Yazawa, and Zenshirou Tamaki, and Ryuichi Ashida, and Masatoshi Jinnin, and Yoshihide Asano, and Yayoi Tada, and Masahide Kubo, and Hironobu Ihn, and Kunihiko Tamaki
October 1989, Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete,
Yoshihiro Mimura, and Norihito Yazawa, and Zenshirou Tamaki, and Ryuichi Ashida, and Masatoshi Jinnin, and Yoshihide Asano, and Yayoi Tada, and Masahide Kubo, and Hironobu Ihn, and Kunihiko Tamaki
November 1986, Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine,
Yoshihiro Mimura, and Norihito Yazawa, and Zenshirou Tamaki, and Ryuichi Ashida, and Masatoshi Jinnin, and Yoshihide Asano, and Yayoi Tada, and Masahide Kubo, and Hironobu Ihn, and Kunihiko Tamaki
October 2005, Rheumatology (Oxford, England),
Yoshihiro Mimura, and Norihito Yazawa, and Zenshirou Tamaki, and Ryuichi Ashida, and Masatoshi Jinnin, and Yoshihide Asano, and Yayoi Tada, and Masahide Kubo, and Hironobu Ihn, and Kunihiko Tamaki
May 2019, La Revue du praticien,
Yoshihiro Mimura, and Norihito Yazawa, and Zenshirou Tamaki, and Ryuichi Ashida, and Masatoshi Jinnin, and Yoshihide Asano, and Yayoi Tada, and Masahide Kubo, and Hironobu Ihn, and Kunihiko Tamaki
April 2006, Nihon Rinsho Men'eki Gakkai kaishi = Japanese journal of clinical immunology,
Copied contents to your clipboard!